97 related articles for article (PubMed ID: 12464652)
21. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.
Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD
J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049
[TBL] [Abstract][Full Text] [Related]
22. Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients.
Weinlich G; Eisendle K; Hassler E; Baltaci M; Fritsch PO; Zelger B
Br J Cancer; 2006 Mar; 94(6):835-41. PubMed ID: 16508630
[TBL] [Abstract][Full Text] [Related]
23. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
[TBL] [Abstract][Full Text] [Related]
24. Bcl2 and Bax expression in naevi and melanomas and their relation to ploidy status and proliferation.
Korabiowska M; Brinck U; Ruschenburg I; Schlott T; Droese M; Stachura J
Pol J Pathol; 1999; 50(1):17-21. PubMed ID: 10412270
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.
Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
[TBL] [Abstract][Full Text] [Related]
26. Identification of metastasis-suppressive microRNAs in primary melanoma.
Hanniford D; Segura MF; Zhong J; Philips E; Jirau-Serrano X; Darvishian F; Berman RS; Shapiro RL; Pavlick AC; Brown B; Osman I; Hernando E
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25677173
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
28. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
29. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
30. Metallothionein-overexpression as a prognostic marker in melanoma.
Weinlich G
G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
[TBL] [Abstract][Full Text] [Related]
31. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
32. S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: a totally dedifferentiated malignant melanoma?
Laskin WB; Knittel DR; Frame JN
Am J Clin Pathol; 1995 Jun; 103(6):772-3. PubMed ID: 7785665
[No Abstract] [Full Text] [Related]
33. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
34. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
35. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
36. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors in thin cutaneous malignant melanoma].
Massi D; Franchi A; Santucci M
Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
[TBL] [Abstract][Full Text] [Related]
38. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
Böni R; Bantschapp O; Müller B; Burg G
Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.
Ci C; Tang B; Lyu D; Liu W; Qiang D; Ji X; Qiu X; Chen L; Ding W
Int J Mol Med; 2019 Jan; 43(1):404-412. PubMed ID: 30431060
[TBL] [Abstract][Full Text] [Related]
40. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]